Navigation Links
Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
Date:6/4/2008

- Company Reports Positive Top-line Results from Second Phase 3 Study of

Intermezzo(R) -

PT. RICHMOND, Calif., June 4 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs, announced today that it has completed all pivotal and supporting clinical trials that will be included in the new drug application (NDA) for its lead product candidate, Intermezzo(R). Following its pre-NDA meeting with the U.S. Food and Drug Administration (FDA) on April 2, 2008, Transcept now expects to submit the Intermezzo(R) NDA in the third quarter of 2008.

Transcept's meeting with the FDA was triggered by the Company's successful completion of a second Phase 3 clinical trial of Intermezzo(R) (3.5 mg zolpidem tartrate sublingual lozenge), a low dose buffered sublingual formulation designed to treat insomnia in patients who awaken in the middle-of-the-night (MOTN) and have difficulty returning to sleep. The randomized, double-blind, placebo-controlled outpatient study involving 294 patients met its primary endpoint of significantly reducing time to sleep onset vs. placebo.

In addition to the Phase 3 outpatient study, Transcept has also completed a Phase 3 double-blind, placebo-controlled crossover sleep-lab study of Intermezzo(R) involving 82 insomnia patients. As announced in June 2007, the sleep-lab study demonstrated that Intermezzo(R) 3.5 mg significantly shortened time to sleep onset in comparison to placebo in patients experiencing middle-of-the-night awakenings. Compared to placebo, patients on the 3.5 mg dose also reported statistically significant improvements in total sleep time, sleep efficiency, subjective number of awakenings post-dose, sleep quality, refreshing sleep, and next day ability to function. Overall, Intermezzo(R) was well tolerated in both Phase 3 studies, and exhibited a safety profile similar to placebo.

Glenn
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... BRUNSWICK, N.J. , May 7, 2015 ... a first-of-its-kind partnership that enlists a third party to ... Johnson & Johnson (Janssen) for compassionate use ... as a pilot program focused on a single Janssen ... that will be applicable more broadly across Johnson & ...
(Date:5/6/2015)... May 6, 2015  Zimmer Holdings, Inc. (NYSE and SIX: ... it will be presenting at the Bank of America Merrill ... in Las Vegas, Nevada on Wednesday, ... A live webcast of the presentation can be accessed via ... will be archived for replay following the conference. ...
(Date:5/6/2015)... 2015  The fairness of the proposed acquisition of ... Pharmaceuticals, Inc. ("Alexion") is being investigated by WeissLaw LLP, ... possible breaches of fiduciary duty and other violations of ... agreeing to sell the Company to Alexion.  On May ... Alexion to acquire GEVA in a transaction valued at ...
Breaking Medicine Technology:Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 2Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 3Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 4Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 5WeissLaw LLP Investigates the Synageva Biopharma Corp. Acquisition 2
... Dec. 9, 2011 /PRNewswire-iReach/ -- Novel Health ... the publication of  2010-2011 market trends study called ,What,s ... The published article is an analysis of sales, pricing, ... specialty biologic products. This study highlights several emerging trends ...
... FRAMINGHAM, Mass. and SYDNEY, Dec. 9, 2011 HeartWare ... HIN), a leading innovator of less invasive, miniaturized circulatory ... heart failure, today announced that CEO Doug Godshall is ... Conference at 10:50 a.m. EST on Wednesday, December 14, ...
Cached Medicine Technology:Biotech Market Trends Study Shows New Competitive Dynamics and Increasing Reimbursement Hurdles 2Biotech Market Trends Study Shows New Competitive Dynamics and Increasing Reimbursement Hurdles 3Biotech Market Trends Study Shows New Competitive Dynamics and Increasing Reimbursement Hurdles 4HeartWare to Present at the Oppenheimer 22nd Annual Healthcare Conference 2
(Date:5/7/2015)... May 07, 2015 Centurion Service ... is proud to announce the upcoming live auction to ... surgery centers and other medical facilities from around the ... including radiology, surgery, endoscopy, lab, anesthesia, infusion, exam and ... Tuesday, May 12 starting at 9:00am PDT. The equipment ...
(Date:5/7/2015)... May 07, 2015 More than most public ... With constant media attention personal issues become public affairs and ... SCI TV , industry expert Katharine Nohr ... profile athletes Justin Gatlin and Michael Phelps. , With a ... her to start her own company, Nohr Sports Risk Management. ...
(Date:5/7/2015)... Wisconsin (PRWEB) May 07, 2015 When people ... give more consideration to their roofs than their basements. However, ... for flooding in crawlspaces and basements. While flooding is an ... to keep crawlspaces and unfinished areas dry to avoid a ... of a Damp Basement, Even small amounts of water can ...
(Date:5/7/2015)... (PRWEB) May 07, 2015 Aureus Medical ... travel nursing jobs and a variety of ... has released an infographic spotlighting top theme parks ... is aimed at thrill-seeking mobile healthcare professionals who are ... Travel healthcare careers offer an opportunity for the travel ...
(Date:5/7/2015)... 07, 2015 Dynamic Path, a leader ... its new free Alcohol Safety Exam Prep module ... restaurant managers, professional bartenders, and any front-of-house staff who ... Certification. The material encompasses topics taught in the National ... students can take the ServSafe Alcohol Proctored Exam or ...
Breaking Medicine News(10 mins):Health News:Centurion to Sell Surplus Medical Equipment in Online and On-site Auction 2Health News:Katharine Nohr Discusses Risk Management in Sports on SCI TV 2Health News:Katharine Nohr Discusses Risk Management in Sports on SCI TV 3Health News:Spring Storms Bring Musty Smell Inside 2Health News:Spring Storms Bring Musty Smell Inside 3Health News:Get to Know the Top Theme Parks: Aureus Medical Releases Infographic for the Travel Nurse and Other Travel Healthcare Professionals 2Health News:Dynamic Path Adds Alcohol Safety Exam Prep Module to Test Preparation Offerings 2
... between ages 15 and 45. When a tumor is found, ... way it's removed, which often leaves men infertile, //can change ... all men who have testicular tumors in one testicle will ... they will have no hormonproduction and no possibility for fertility. ...
... fight another. Researchers say the little-known virus GBV-C, also ... a key to helping researchers devise new strategies against ... Multicenter Acquired Immunodeficiency Syndrome Cohort Study, in which investigators ... United States for more than 15 years. The study ...
... fluids may do more harm than good for patients ... previous studies to determine if recommending patients with respiratory ... shown during a respiratory infection, such as a cold ... specific hormone that conserves water. Thus, researchers say giving ...
... errors that occur in pediatric intensive care units are more ... more than 11,800 children who were admitted into pediatric intensive ... defined an error as any preventable event that may cause ... were reported during the course of the study. Nearly 70 ...
... can no longer be considered a benign condition or ... 60 percent of overweight children have at least one ... type 2 diabetes is increasing rapidly in developing countries ... 2 diabetes in developing countries has been attributed to ...
... or other painkillers that is characterized by the onset ... after taking the medications. British researchers analyzed more than ... percent of adults and about 5 percent of children ... these patients were also sensitive to over-the-counter non-steroidal anti-inflammatory ...
Cached Medicine News:Health News:Childhood Weight Gain Found To Increase The Risk of Diabetes 2
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
... optimize the accuracy and precision of Finnpipettes. ... widely recognized by customers throughout the world. ... the years and now covers a full ... filter tips, certified pure tips, stepper tips ...
MBP's 200 L large orifice tip is perfect for handling fragile cells, viscous samples and genomic....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
Medicine Products: